249 related articles for article (PubMed ID: 30673118)
1. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
2. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
[TBL] [Abstract][Full Text] [Related]
3. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
5. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
7. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C prevalence and cascade of care among patients in the decentralised opioid agonist therapy programme of the canton of St Gallen, Switzerland: a cross-sectional study.
Wissel K; Vernazza P; Kuster S; Hensel-Koch K; Bregenzer A
Swiss Med Wkly; 2024 Feb; 154():3352. PubMed ID: 38579293
[TBL] [Abstract][Full Text] [Related]
10. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
[TBL] [Abstract][Full Text] [Related]
11. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
[TBL] [Abstract][Full Text] [Related]
12. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
13. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
14. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
Willemse SB; Razavi-Shearer D; Zuure FR; Veldhuijzen IK; Croes EA; van der Meer AJ; van Santen DK; de Vree JM; de Knegt RJ; Zaaijer HL; Reesink HW; Prins M; Razavi H
Neth J Med; 2015 Nov; 73(9):417-31. PubMed ID: 26582807
[TBL] [Abstract][Full Text] [Related]
15. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
17. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
Tergast TL; Blach S; Tacke F; Berg T; Cornberg M; Kautz A; Manns M; Razavi H; Sarrazin C; Serfert Y; van Thiel I; Zeuzem S; Wedemeyer H
J Viral Hepat; 2022 Jul; 29(7):536-542. PubMed ID: 35357770
[TBL] [Abstract][Full Text] [Related]
18. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
19. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
20. Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project.
van Dijk M; Kracht PAM; Arends JE; Blokzijl H; Burger DM; van Erpecum KJ; van Hoek B; de Knegt RJ; Posthouwer D; Ramsoekh D; Rijnders BJA; Schinkel J; Willemse SB; van der Valk M; Drenth JPH; Behalf Of The HepNed Study Group O
Neth J Med; 2019 May; 77(4):131-138. PubMed ID: 31502544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
